Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer
NCT03429101Phase 1Terminated
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- Jul 2018
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of poziotinib in HER2-positive breast cancer, sponsored by Spectrum Pharmaceuticals, Inc. Primary endpoint: Objective Response Rate at 3 years. Started Jul 2018; status: terminated.
02
Drugs
poziotinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT03429101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03429101.